No products in the cart.
Pre-made Etesevimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-196
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Etesevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS-CoV-2.
| Products Name (INN Index) | Pre-Made Etesevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
|---|---|
| INN Name | Etesevimab |
| Target | SARS-CoV-2 Spike RBD |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | 7c01:CD |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Eli Lilly and Company,Institute of Microbiology of the Chinese Academy of Sciences,Shanghai Junshi Biosciences |
| Conditions Approved | COVID-19 |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SARS-CoV-2 Spike RBD |
| Package |
Previous slide
Next slide
